Smith-Lemli-Opitz syndrome produced in rats with AY 9944 treated by intravenous injection of lipoprotein cholesterol

American Journal of Medical Genetics

Volumn 68, Issue 3, 1997, Pages 322-327

  Chambers, Christopher M ^a   McLean, Mark P ^a   Ness, Gene C ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

AY 9944; intravenous lipoprotein cholesterol; Smith Lemli Opitz syndrome

Indexed keywords

CHOLESTEROL;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DIET SUPPLEMENTATION; FAT INTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMITH LEMLI OPITZ SYNDROME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, DIETARY; COMBINED MODALITY THERAPY; DEHYDROCHOLESTEROLS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INJECTIONS, INTRAVENOUS; LIPOPROTEINS; MALE; OXIDOREDUCTASES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; RATS; RATS, SPRAGUE-DAWLEY; SMITH-LEMLI-OPITZ SYNDROME; TRANS-1,4-BIS(2-CHLOROBENZAMINOMETHYL)CYCLOHEXANE DIHYDROCHLORIDE;

ANIMALIA; BOVINAE;

EID: 0031056894     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19970131)68:3<322::AID-AJMG14>3.0.CO;2-V     Document Type: Article

References (15)

1. Irons M, Elias ER, Abuelo D, Tint GS, Sälen G (1995): Clinical features of the Smith-Lemli-Opitz syndrome and treatment of the cholesterol metabolic defect. Int Pediatr 10:28-32.
2. Leonard DA, Kotarski MA, Tessiatore JE, Favata MF, Trzaskos JM (1994): Posttransciptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by 3β-hydroxy-lanost-8-en-32 al, an intermediate in the conversion of lanosterol to cholesterol. Arch Biochem Biophys 310:152-157.
3. Lowry RB, Young SL (1980): Borderline intelligence in the SmithLemli-Opitz syndrome. Am J Med Genet 5:413-425.
4. Natowicz MR, Evans JE (1994): Abnormal bile acids in the SmithLemli-Opitz syndrome. Am J Med Genet 50:364-367.
5. Ness GC, Pendleton LC, Pendleton AS (1987): Loss of NADPH during assays of HMG-CoA reductase: Implications and approaches to minimize errors. Lipids 22:409-412.
6. Ness GC, Keller RK, Pendleton LC (1991): Feedback regulation of hepatic 3-hydroxy-3-methlyglutaryl coenzyme A reductase activity by dietary cholesterol is not due to altered mRNA levels. J Biol Chem 266:14854-14857.
7. Ness GC, Eales S, Lopez D, Zhao Z (1994): Regulation of 3-hydroxy-3methylglutaryl coenzyme A reductase gene expression by sterols and nonsterols in rat liver. Arch Biochem Biophys 308:420-425.
8. Ness GC, Zhao Z, Lopez D (1996): Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation. Arch Biochem Biophys 325:242-248.
9. Ness GC, Lopez D, Borrego O, Gilbert-Harness E (1997): Increased expression of low density lipoprotein receptor in a Smith-LemliOpitz infant with elevated bilirubin levels. Am J Med Genet 68: 294-299.
10. Salcn G, Shefer S, Batta AK, Tint GS (1995): Biochemical abnormalities in the Smith-Lemli-Opitz syndrome. Int Pediatr 10:33-36.
11. Smith DW, Lemli L, Opitz JM (1964): A newly recognized syndrome of multiple congenital anomalies. J Pediatr 64:210-217.
12. Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, Salen G (1994): Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 330:107-113.
13. Tint GS, Salen G, Batta AK, Shefer S, Irons M, Elias ER, Abuelo DN (1995): Correlation of severity and outcome with plasma sterol levels in variants of the Smith-Lemli-Opitz syndrome. J Pediatr 127:82-87.
14. Trzaskos JM (1995): Oxylanosterols as modifiers of cholesterol biosynthesis. Prog Lipid Res 34:99-116.
15. Xu G, Salen G, Shefer S, Ness GC, Chen TS, Zhao Z, Tint GS (1995): Reproducing abnormal cholesterol biosynthesis as seen in SmithLemli-Opitz syndrome by inhibiting the conversion of 7-dehydrocholesterol to cholesterol in rats. J Clin Invest 95:76-81.